NOWDiagnostics
NOWDiagnostics develops and manufactures 'Touch to Test' diagnostic tests that provide rapid results using minimal samples, offering a variety of tests including COVID-19 and Syphilis. The company operates in 10 countries and has sold 320,000 tests.
About NOWDiagnostics
NOWDiagnostics develops and manufactures 'Touch to Test' over-the-counter and point-of-care diagnostic tests that yield results in minutes. These tests use a patented approach that allows virtually any immunological assay to be accurately performed onsite in one step using a tiny amount of capillary blood or, in some cases, saliva. The company is headquartered at 1200 Stewart Place, Springdale, AR 72764 and operates in 10 countries with 14 distributors. Over 320,000 tests have been sold, showcasing the company’s significant reach in the diagnostic testing market.
Diagnostic Tests by NOWDiagnostics
NOWDiagnostics offers a range of diagnostic tests under the ADEXUSDx® brand. These include the ADEXUSDx® COVID-19 Test for detecting total antibodies to SARS-CoV-2, the ADEXUSDx® hCG Test for detecting human chorionic gonadotropin, and the ADEXUSDx® Syphilis Test for detecting syphilis antibodies. Other products include the ADEXUSDx® H-FABP Test, ADEXUSDx® Troponin I Test, ADEXUSDx® Salicylate Test, ADEXUSDx® Methanol Dip Test, ADEXUSDx® Acetaminophen Test, and the ADEXUSDx® Troponin I/Myoglobin Test.
Patent and Technology
NOWDiagnostics employs a patented approach that simplifies diagnostic testing, enabling virtually any immunological assay to be performed onsite in one step. Their technology uses a tiny amount of capillary blood or, in some cases, saliva, which facilitates quick and accurate results. This innovation has substantial implications for both over-the-counter and point-of-care diagnostics, allowing for broader application and ease of use.
Regulatory Approvals and Certifications
NOWDiagnostics has received various regulatory approvals and certifications for its products. The ADEXUSDx® COVID-19 Test has been granted FDA Emergency Use Authorization. Additionally, the company received a CE Mark for the ADEXUSDx® Syphilis rapid test, signifying compliance with European health, safety, and environmental protection standards. A De Novo Classification Request for the First to Know™ Over-the-Counter Syphilis Test has also been submitted to the FDA.
Funding and Partnerships
NOWDiagnostics has received funding from Labcorp's Venture Fund to advance its diagnostic breakthroughs. This financial backing supports the company’s mission to innovate and expand its range of rapid diagnostic tests. The collaboration with a well-established entity like Labcorp signifies the growing trust and potential in NOWDiagnostics' product offerings.